Term
|
Definition
Acetohexamide
Sulfonylurea 1st Generation |
|
|
Term
|
Definition
Chlorpropamide
Sulfonylurea 1st Generation
contraindicated in renal insufficience |
|
|
Term
|
Definition
Tolazamide
Sulfonylurea 1st Generation |
|
|
Term
|
Definition
Tolbutamide
Sulfonylurea 1st Generation |
|
|
Term
|
Definition
Glipizide
Sulfonylurea 2nd Generation
Given with or without meal |
|
|
Term
|
Definition
Glyburide
Sulfonylurea 2nd Generation
3 mg Glynase = 5 mg Glyburide |
|
|
Term
|
Definition
Lyburide micronized
Sulfonylurea 2nd Generation |
|
|
Term
|
Definition
Glimepiride
Sulfonylurea 2nd Generation
Begin with 1 mg in renal insufficience |
|
|
Term
|
Definition
Repaglinide
Meglitinides
Skip dose if meal skipped |
|
|
Term
|
Definition
Nateglinide
Meglitinide
Efficacy: prandin> starlix |
|
|
Term
|
Definition
Metformin
Biguanide
Do not give if femal SrCr >1.4, Male SrCR >1.5 |
|
|
Term
|
Definition
Metformin Extended release
Biguanide |
|
|
Term
|
Definition
Rosiglitazone
Thiazoladinedions
May be more effective if given BID
Contranidicated in Heart Failure |
|
|
Term
|
Definition
Pioglitazone
Thiazoladinediones |
|
|
Term
|
Definition
Acarbose
Alpha-Glucosidase Inhibitor |
|
|
Term
|
Definition
Miglitol
Alpha-glucosidase inhibitor |
|
|
Term
|
Definition
Saxagliptin
Dipeptidyl Peptidase-4 Inhibitor'
CrCl <50ml/min give 2.5mg qd |
|
|
Term
|
Definition
Linagliptin
Dipeptidyl Peptidase-4 Inhibitor
Not dependent on CrCl |
|
|
Term
|
Definition
Sitagliptin
Dipeptidyl Peptidase-4 Inhibitor
Dosed based on CrCl |
|
|
Term
|
Definition
| Combo: Glipizide/Metformin |
|
|
Term
|
Definition
| Combo: Glyburide/Metformin |
|
|
Term
|
Definition
| Combo: Glimepiride/Rosigitazone |
|
|
Term
|
Definition
| Combo: Glimepiride/Pioglitazone |
|
|
Term
|
Definition
| Combo: Rosiglitazone/ metformin |
|
|
Term
|
Definition
| Combo: Metformin/Pioglitazone |
|
|
Term
|
Definition
| combo: Metformin/ Januvia (Sitagliptin) |
|
|
Term
|
Definition
| Combo: Metformin/ Repaglinide (meglitinide) |
|
|
Term
|
Definition
| Combo: Metformin/Saxagliptin (DDP4) |
|
|
Term
|
Definition
| Combo: Metformin/ Linagliptin (DDp4) |
|
|
Term
|
Definition
Liraglutide
duration of action ~24 hrs
Incretin Mimetic
Dosed once daily reglardless of meals |
|
|
Term
|
Definition
Exenatide
duration of action ~8-10 hrs
Incretin Mimetic
dosed 10-15 minutes prior to 2 largests meals of the day |
|
|
Term
|
Definition
Exenatide
~2 weeks initail peak, stead state 6-7
Dosed weekly reglardless of meals
Incretin mimetic |
|
|
Term
|
Definition
Pramlintide
Amylin Mimetic |
|
|
Term
|
Definition
Glulisine
Rapid Acting Insulin
peak 30-90 Minutes
DA: 1-3 hrs |
|
|
Term
|
Definition
Aspart
Rapid acting insulin
peak 30-90 Minutes
DA: 3-5hrs |
|
|
Term
|
Definition
Lispro
Rapid actic insulin
peak 30-90 Minutes |
|
|
Term
|
Definition
Human NPH
Peak: 4-12 hrs
Duration of action 10-18 Hours |
|
|
Term
|
Definition
Human NPH
Peak: 4-12 hrs
Duration of action 10-18 Hours |
|
|
Term
|
Definition
Lente Human
Time to peak: 7-15
Duration: 24 hr |
|
|
Term
|
Definition
Glargine
Basal Insulin
Peakless
DA 24 hours |
|
|
Term
|
Definition
Detemir insulin
Peak: 6-8 hrs
Duration of action 19-24 hrs |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Insulin aspart protamin + insulin lispro
intermedia + rapid |
|
|
Term
|
Definition
Insulin aspart protamin + insulin lispro
intermedia + rapid |
|
|
Term
|
Definition
Insulin lispro protamin + insulin lispro
intermedia + rapid |
|
|
Term
|
Definition
Insulin lispro protamin + insulin lispro
intermediate + rapid |
|
|
